Gene therapy and angiogenesis in patients with coronary artery disease

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 8, 2010, Pages 1127-1138

  Kastrup, Jens ^a  

^a Rigshospitalet   (Denmark)

Author keywords

angiogenesis; FGF; gene therapy; ischemic heart; stem cell; vascular growth factors; VEGF

Indexed keywords

PLACEBO; RECOMBINANT FIBROBLAST GROWTH FACTOR; RECOMBINANT FIBROBLAST GROWTH FACTOR 2; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GROWTH FACTOR; RECOMBINANT VASCULOTROPIN; RECOMBINANT VASCULOTROPIN A165; UNCLASSIFIED DRUG; ANGIOGENIC FACTOR; FIBROBLAST GROWTH FACTOR; VASCULOTROPIN;

ANGIOGENESIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSFECTION; HUMAN; HYPOTENSION; ISCHEMIC HEART DISEASE; NONHUMAN; PROTEINURIA; REVASCULARIZATION; REVIEW; STEM CELL TRANSPLANTATION; THORACOTOMY; THROMBOCYTOPENIA; ANIMAL; CLINICAL TRIAL (TOPIC); PATHOPHYSIOLOGY; PROCEDURES; SEVERITY OF ILLNESS INDEX;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; FIBROBLAST GROWTH FACTORS; GENETIC THERAPY; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; SEVERITY OF ILLNESS INDEX; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 77955219393     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.10.95     Document Type: Review

References (58)

1. Ahn A, Frishman WH, Gutwein A, Passeri J, Nelson M. Therapeutic angiogenesis: a new treatment approach for ischemic heart disease-part I. Cardiol. Rev. 16(4), 163-171 (2008).
2. Ahn A, Frishman WH, Gutwein A, Passeri J, Nelson M. Therapeutic angiogenesis: a new treatment approach for ischemic heart disease-part II. Cardiol. Rev. 16(5), 219-229 (2008).
3. Taljaard M, Ward MR, Kutryk MJ et al Rationale and design of Enhanced Angiogenic Cell Therapy in Acute Myocardial Infarction (ENACT-AMI): the first randomized placebo-controlled trial of enhanced progenitor cell therapy for acute myocardial infarction. Am. Heart J. 159(3), 354-360 (2010).
4. Banai S, Jaklitsch MT, Shou M et al. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 89, 2183-2189 (1994).
5. Takeshita S, Zheng LP, Brogi E et al. Therapeutic angiogenesis: a single intra-arterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hindlimb model. J. Clin. Invest. 93, 662-670 (1994).
6. Schumacher B, Stegmann T, Pecher P. The stimulation of neoangiogenesis in the ischemic human heart by the growth factor FGF: first clinical results. J. Cardiovasc. Surg. 39, 783-789.
7. Sellke FW, Laham RJ, Edelman Er et al. Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. Ann. Thorac. Surg. 65, 1540-1544 (1998).
8. Laham R, Sellke FW, Edelman ER et al. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery. Circulation 100, 1865-1871.
9. Ruel M, Laham RJ, Parker JA et al. Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J. Thorac. Cardiovasc. Surg. 124, 28-34 (2002).
10. Laham RJ, Chronos NA, Marilyn P et al. Intracoronary basic fibroblast growth factor (FGF-2) in patients with ischemic heart disease: Results of a Phase I open-label dose escalation study. J. Am. Coll. Cardiol. 36, 2132-2139 (2000).
11. Unger EF, Goncalves L, Epstein SE et al. Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris. Am. J. Cardiol. 85, 1414-1419 (2000).
12. Simons M, Annex BH, Laham RJ et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2. Double-blind, randomized, controlled clinical trial. Circulation 105, 788-793 (2002).
13. Hendel RC, Henry TD, Rocha-Singh K et al. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. Circulation 101, 118-121 (2000).
14. Henry TD, Annex BH, McKendall GR et al. for the VIVA Investigators. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation. 107(10), 1359-1365 (2003).
15. Sato K, Laham RJ, Pearlman JD et al. Efficacy of intracoronary versus intravenous FGF-2 in a pig model of chronic myocardial ischemia. Ann. Thorac. Surg. 70, 2113-2118 (2000).
16. Laitinen M, Hartikainen J, Hiltunen MO et al. Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty. Hum. Gene Ther. 11, 263-270 (2000).
17. Hedman M, Hartikainen J, Syvanne M et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia. Phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 107, 2677-2683 (2003).
18. Grines CL, Watkins MW, Helmer G et al. Angiogenic gene therapy (AGENT) trial in patients with stable angina pectoris. Circulation, 105,1291-1297(2002).
19. Grines CL, Watkins MW, Mahmarian JJ et al. for the Angiogenic Gene Therapy (AGENT-2) study group. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J. Am. Coll. Cardiol. 42, 1339-1347 (2003).
20. Henry TD, Grines CL, Watkins MW et al. Effects of Ad5FGF-4 in patients with angina. An analysis of pooled data from the AGENT-3 and AGENT-4 trials. J. Am. Coll. Cardiol. 50, 1038-1046.
21. Kastrup J, Jorgensen E, Drvota V et al.; the EUROINJECT ONE group. Intra-myocardial injection of genes by a novel percutaneous technique. Initial safety data in the EUROINJECT ONE study. Heartdrug 1, 299-304 (2001).
22. Baldazzi F, Jorgensen E, Ripa RS, Kastrup J. Release of biomarkers of myocardial damage after direct intramyocardial injection of genes and stem cells via the percutaneous transluminal route. Eur. Heart J. 29(15), 1819-1826.
23. Symes JF, Losordo DW, Vale PR et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann. Thorac. Surg. 68, 830-837 (1999).
24. Sylven C, Sarkar N, Ruck A et al. Myocardial doppler tissue velocity improves following myocardial gene therapy with VEGF-A plasmid in patients with inoperable angina pectoris. Coron. Artery Dis. 12, 239-243 (2001).
25. Sarkar N, Ruck A, Kallner et al. Effects of intra myocardial injection of phVEGF-A165 as sole therapy in patients with refractory coronary artery disease - 12 months follow-up: angiogenic gene therapy. J. Intern. Med. 250(5), 373-381 (2001).
26. Rosengart T, Lee LY, Patel SR et al. Angiogenesis gene therapy. Phase I assessment of direct intra-myocardial administration of an adenovirus vector expressing VEGF cDNA to individuals with clinically significant severe coronary artery disease. Circulation 100, 468-474 (1999). (Pubitemid 29360154)
27. Fuchs S, Dib N, Cohen BM et al. A randomized, double-blind, placebo-controlled, multicenter, pilot study of the safety and feasibility of cather-based intramyocardial injection of AdVEGFm in patients with refractory advanced coronary artery disease. Catheter. Cardiovasc. Interv. 68, 372-378 (2006).
28. Stewart DJ, Arnold JMO, Gregoire J et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a Phase 2 randomized, controlled trial of AdVEGF121 (AdVEGF121) versus maximum medical treatment. Gene Ther. 13(21), 1503-1511 (2006).
29. Kastrup J, Jorgensen E, Fuchs S et al. A randomized, double-blind, placebo-controlled, multicenter study of the safety and efficacy of BIOBYPASS (AdGyVEGF121.10NH)gene therapy in patients with refractory advanced coronary artery disease. The NOVA trial. Eurolntervention (2010) (In Press).
30. Vale PR, Losordo DW, Milliken CE et al. Randomised, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients chronic myocardial ischemia. Circulation 103, 2138-2143 (2001).
31. Losordo DW, Vale PR, Hendel RC et al. Phase 1/2 placebo-controlled, doubleblind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 105, 2012-2018 (2002).
32. Tio RA, Tan ES, Jessurun GA et al. PET for evaluation of differential myocardial perfusion dynamics after VEGF gene therapy and laser therapy in end-stage coronary artery disease. J. Nucl. Med. 45(9), 1437-1443 (2004).
33. Kastrup J, Joergensen E, Ruck A et al. for the EUROINJECT ONE Group. Direct intra-myocardial plasmid vascular endothelial growth factor-A gene therapy in patients with stable angina pectoris - a randomized double-blind placebo- controlled study. The EUROINJECT ONE Trial. J. Am. Coll. Cardiol. 45, 982-988 (2005).
34. Gyongyosi M, Khorsand A, Zamini S et al. NOGA-guided analysis of regional myocardial perfusion abnormalities treated with intra-myocardial injections of plasmid encoding VEGF A-165 in patients with chronic myocardial ischemia. Subanalysis of the EUROINJECT-ONE multicenter double-blind randomized study. Circulation 112(Suppl I) 1157-1165 (2005).
35. Stewart DJ, Kutryk MJB, Fitchett D et al. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary artery disease: results of the NORTHERN trial. Mol. Med. 17, 1109-1115 (2009).
36. Kawamoto A, Gwon HC, Iwaguro H et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 103, 634-637 (2001).
37. Orlic D, Kajstura J, Chimenti S et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc. Natl Acad. Sci. USA 98, 10344-10349 (2001).
38. Schachinger V, Assmus B, Britten MB et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI trial. J. Am. Coll. Cardiol. 44, 1690-1699 (2004).
39. Janssens S, Dubois C, Bogaert J et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double- blind, randomised controlled trial. Lancet 367(9505), 113-121 (2006).
40. Lunde K, Solheim S, Aakhus S et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N. Engl. J. Med. 355(12), 1199-1209 (2006).
41. Perin EC, Dohmann HF, Borojevic R et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 107, 2294-2302 (2003).
42. Haack-Sorensen M, Friis T, Kastrup J. Mesenchymal stromal cell and mononuclear cell therapy in heart disease. Future Cardiol. 4, 481-494 (2008).
43. Mathiasen AB, Haack-Sorensen M, Kastrup J. Mesenchymal stromal cells for cardiovascular repair: current status and future challenges. Future Cardiol. 5, 605-617 (2009).
44. Wang Y, Tagil K, Ripa RS et al. Effect of mobilization of bone marrow stem cells by granulocyte colony stimulating factor on clinical symptoms, left ventricular perfusion and function in patients with severe chronic ischemic heart disease. Int. J. Cardiol. 100, 477-483 (2005).
45. Hill JM, Syed MA, Arai AE et al. Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. J. Am. Coll. Cardiol. 46, 1643-1648 (2005).
46. Zohlnhofer D, Dibra A, Koppara T et al. Stem cell mobilisation by G-CSF for myocardial recovery after acute myocardial infarction: a meta-analysis. J. Am. Coll. Cardiol. 51(15), 1429-1437 (2008).
47. Ripa RS, Jorgensen E, Wang Y et al. Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction. Result of the Double-Blind, Randomized, Placebo-Controlled Stem Cells in Myocardial Infarction (STEMMI) Trial. Circulation 113, 1983-1992 (2006).
48. Kawamoto A, Murayama T, Kusano K et al. Synergistic effect of bone marrow mobilization and vascular endothelial growth factor-2 gene therapy in myocardial ischemia. Circulation 110, 1398-1405 (2004).
49. Ripa R, Wang Y, Jorgensen E, Johnsen HE, Hesse B, Kastrup J. Direct intra- myocardial injection of vascular endothelial growth factor-Al65 plasmid followed by granulocyte-colony stimulating factor treatment to mobilize stem cells and promote myocardial homing to induce angiogenesis in patients with severe chronic ischemic heart disease. Eur. Heart J. 27(15), 1785-1792 (2006).
50. Isner JM, Vale PR, Symes JF, Losordo DW. Assessment of risks associated with cardiovascular gene therapy in human subjects. Circ. Res. 89, 389-400 (2001).
51. Wang Y, Johnsen HE, Mortensen S et al. Changes in circulating mesenchymal stem cells, stem cell homing factor, and vascular growth factors in patients with acute ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Heart 92(6), 768-774 (2006).
52. Wang Y, Gabrielsen A, Lawler PR et al. Myocardial gene expression of angiogenic factors in human chronic ischemic myocardium - influence of acute ischemia/cardioplegia and reperfusion. Microcirculation 13, 187-197 (2006).
53. Abbott JD, Huang Y, Liu D, Hickey R, Krause DS, Giordano FJ. Stromal cell-derived factor-1a plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation 110, 3300-3305
54. Hiasa K, Ishibashi M, Ohtani K et al. Gene transfer of stromal cell-derived factor-1a enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: next-generation chemokine therapy for therapeutic neovascularization. Circulation 109, 2454-2461 (2004).
55. Yang J, Zhou W, Zheng W et al. Effects of myocardial transplantation of marrow mesenchymal stem cells transfected with vascular endothelial growth factor for the improvement of heart function and angiogenesis after myocardial infarction. Cardiology 107, 17-29 (2007).
56. Yau TM, Kim C, Ng D et al. Increased transplanted cell survival with cell-based angiogenic gene therapy. Ann. Thorac. Surg. 80, 1779-1786 (2005).
57. Heiss C, Keymel S, Niesler U et al. Impaired progenitor cell activity in age-related endothelial dysfunction. J. Am. Coll. Cardiol. 45,1441-1448
58. Kobulnik J, Kuliszewski MA, Stewart DJ, Lindner JR, Leong-Poi H. Comparison of gene delivery techniques for therapeutic angiogenesis ultrasound-mediated destruction of carrier microbubbles versus direct intramuscular injection J. Am. Coll. Cardiol. 54(18), 1735-1742 (2009).